Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Similar articles for PubMed (Select 23872628)

1.

Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.

Heidenreich A, Porres D, Piper C, Thissen AK, Pfister D.

Minerva Urol Nefrol. 2013 Sep;65(3):171-87.

PMID:
23872628
2.

Perspectives on treatment of metastatic castration-resistant prostate cancer.

Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM; European Treatment Practices Group.

Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Review. Erratum in: Oncologist. 2013;18(8):971. Oncologist. 2013;18(6):775.

3.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
4.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
5.

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.

Fernández O, Afonso J, Vázquez S, Campos B, Lázaro M, León L, Antón Aparicio LM.

Anticancer Drugs. 2014 Mar;25(3):237-43. doi: 10.1097/CAD.0000000000000045. Review.

PMID:
24217332
6.

New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?

Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S.

J Oncol Pharm Pract. 2014 Dec;20(6):417-25. doi: 10.1177/1078155213509505. Epub 2013 Nov 14.

PMID:
24243919
7.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Review.

8.

[Treatment of metastatic castration-resistant prostate cancer].

Caffo O.

Recenti Prog Med. 2015 Jan;106(1):35-9. doi: 10.1701/1740.18958. Italian.

PMID:
25621779
9.

Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.

Saad F, Miller K.

Urol Oncol. 2014 Feb;32(2):70-9. doi: 10.1016/j.urolonc.2013.01.005. Epub 2013 Mar 15.

PMID:
23506965
10.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189. Epub 2013 Nov 21.

PMID:
24255983
11.

The economics of abiraterone acetate for castration-resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175-9. doi: 10.1586/14737167.2014.891444. Epub 2014 Feb 25.

PMID:
24564607
12.

Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.

Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8. Review.

PMID:
24289901
13.

Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.

Miyake H, Sakai I, Terakawa T, Harada K, Fujisawa M.

Urol Oncol. 2013 Aug;31(6):733-8. doi: 10.1016/j.urolonc.2011.06.006. Epub 2011 Jul 22.

PMID:
21782481
14.

[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].

Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szûcs M, Berczi C, Gulácsi L.

Magy Onkol. 2014 Sep;58(3):189-97. Epub 2014 Aug 2. Review. Hungarian.

15.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

PMID:
25242736
16.

Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?

Oudard S, Angelergues A.

Nat Rev Urol. 2014 Jul;11(7):370-2. doi: 10.1038/nrurol.2014.144. Epub 2014 Jun 24.

PMID:
24960604
17.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948
18.

[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].

Basset V, Flamand V, Crouzet S, Ploussard G.

Prog Urol. 2013 Oct;23 Suppl 1:S44-8. doi: 10.1016/S1166-7087(13)70045-9. Review. French.

PMID:
24314738
19.

Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Malik Z, Payne H, Ansari J, Chowdhury S, Butt M, Birtle A, Sundar S, Eswar CV, Hughes S, Bahl A.

Adv Ther. 2013 Dec;30(12):1041-66. doi: 10.1007/s12325-013-0070-z. Epub 2013 Nov 26. Review.

PMID:
24276853
20.

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J.

BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.

PMID:
22429837
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk